Followers | 826 |
Posts | 119567 |
Boards Moderated | 14 |
Alias Born | 09/05/2002 |
Monday, January 08, 2018 9:59:17 PM
Moreover, Eylea is a fusion protein (as is Orencia), which means it will be technically more difficult to attain bioequivalence to the reference product than it would with a simpler protein such as Xolair.
Technical difficulty has been MNTA’s calling card, but some projects might be too difficult even for MNTA, and we don’t want a repeat of what happened with Orencia.
All told, I’m not convinced that Eylea is a smarter choice for MNTA/MYL than Xolair would have been.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM